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Evidence as to whether clinician has to give specific treatment in all patients of catamenial
hemoptysis is unclear. We considered that the current treatment such as long-term usage
of hormonal agent or surgery might be excessive for the catamenial hemoptysis.
Therefore, we developed prospective observation study with observation strategy and
follow-up for the patients.
In sequential four patients of catamenial hemoptysis between December 2000 and
November 2001, physical examination, chest X-ray, pelvic ultrasonogram and chest CTscan
were taken at both the diagnosis and last follow-up. All patients were only observed
without specific treatment within the limit of the possibility and followed for average 58
months.
Mean age of patients was 23.5 years (range, 22–25 years). All patients have a history of
undertaking one or two dilatations and curettages before diagnosis. The chest CT scans of
all patients presented with ground-glass opacities of peripheral location that were
disappeared without any residual lesion at last follow-up. Hemoptysis of two patients was
spontaneously disappeared after 6 months. In the other two patients, it was greatly
lessened in amount and frequency, then clinically insignificant in one. It was disappeared
after subsequent 2 months and then relapsed two times in the late of follow-up of another
patient.Elsevier Ltd. All rights reserved.
University Research Grant (INHA).
890 3738; fax: +82 32 882 6578.
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Therapeutic implications of patients with catamenial hemoptysis 1033This study suggests that observation only may be an alternative option in the treatment of
catamenial hemoptysis.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Although endometriosis has been noted in 10–15% of women
of reproductive age, catamenial hemoptysis is an extremely
rare clinical subset. To our knowledge, only approximately
40 cases have been reported in the world. In the manage-
ment of hemoptysis by other etiologies, surgical resection
has been limitedly used in the massive, life-threatening
hemoptysis. Most cases of catamenial hemoptysis in previous
reports featured small quantities. There has been no report
of a patient with catamenial hemoptysis showing massive or
fatal hemoptysis.1 Furthermore, substantial rates of adverse
effects and relapse have been reported in patients receiving
hormonal agents in catameninal hemoptysis as well as pelvic
endometriosis.2–5 Various modalities from long-term use of
hormonal agents to surgical resection such as lobectomy
have been tried in the treatment of catamenial hemopty-
sis.3,4,6–17 However, this information has largely arisen from
case reports and experiences from pelvic endometriosis.
Meanwhile, the natural history and pathogenesis of the
catamenial hemoptysis remain largely unknown. We con-
sidered that the current treatment might be excessive for
the catamenial hemoptysis and therefore developed ob-
servation strategy and follow-up for patients with catame-
nial hemoptysis.
Here, we report our experience with four consecutive
female patients with catamenial hemoptysis who did not
receive any specific treatment for the hemoptysis. The
follow-up results suggest that observation may be an
alternative option in the treatment.Materials and methods
In this study, we initially included six patients who presented
to the out-patient clinic of Inha university hospital between
December 2000 and November 2001 and who was clinically
suspicious of catamenial hemoptysis based upon the history.
While three patients complained of recurrent bouts of
hemoptysis during menstruation, the other three patients
presented with her first episode of hemoptysis in the
menstruation. During the follow-up, two of three patients
were excluded because hemoptysis of two patients was not
appeared in subsequent. In four patients, catamenial
hemoptysis was clinically diagnosed with the characteristic
clinical history and chest CT scan finding. Ground-glass
opacities (GGO) that were observed on chest CT scan during
menstruation were resolved during the subsequent inter-
menstrual period in all patients. In addition to physical
examination, chest X-ray and laboratory testing, detailed
history was taken by Song ES, a doctor of the department of
obstetrics and gynecology. Pelvic ultrasonograms were
undertaken at the time of diagnosis and last follow-up. To
evaluate the residual change on the lung, chest CT scan was
taken again at last follow-up. All four patients agreed withour policy of observation only without specific treatment,
hormonal agents or palliative surgical resection, for the
hemopysis treatment. If hemoptysis became more severe in
subsequent menstrual cycles, hormonal agents or surgical
resection could be considered in a revised treatment plan.
The Institutional Review Board of Inha university hospital
approved the study and all patients provided informed
consent (Fig. 1).Results
All four patients were single women (mean age, 23.5 years;
range, 22–25 years) without history of pulmonary, cardio-
vascular or connective tissue diseases. No patients had prior
history of hemoptysis in inter-menstrual period or endome-
triosis. Presenting symptoms other than hemoptysis were
cough ing (patient nos. 1–3) and chest discomfort (patient
no. 4). Physical examinations, chest X-ray, all laboratory
tests, and pelvic ultrasonograms at both of diagnosis and last
follow-up were normal in all four patients. One or two
dilatations and curettages were undertaken before the
diagnosis in all patients (Table 1). Sputum gram stain and
culture for bacteria were negative on the sputum of three
patients who could expectorate. Direct sputum examination
produced negative results for acid-fast organisms and fungi.
No endometrial cells were noted on the sputum. The mean
duration of the concurrent occurrence of hemoptysis with
menstruation prior to the diagnosis was 7.25 months (range,
0–15 months). Chest CT findings of all patients were GGO.
No patients presented with consolidation, nodule(s) or
findings suggesting other causes of hemoptysis such as
tuberculosis, bronchiectasis, or pulmonary embolism on
the CTscans. The mean duration of follow-up was 58 months
(range, 54–66 months). After the diagnosis, patient no. 1,
who presented with 5mL/day of hemoptysis, subsequently
experienced continuation of hemoptysis of streaky blood at
approximate 3-month intervals, during the 55 months of
follow-up. In October 2004, she complained of right lower
abdominal pain and was diagnosed with pelvic endometrio-
sis. Her pain was relieved with oral contraceptive for 4
months. Hemoptysis of patient no. 2, who presented with
5mL/day of hemoptysis, also was greatly lessened in
amount, then spontaneously disappeared 6 months later,
and did not recur during the 54 months of follow-up. She
received second dilatation and curettage in August 2003 and
did not take any hormonal agents during the follow-up.
Patient no. 3 presented with two episodes of hemoptysis (30
and 15mL/day, respectively). After two more subsequent
episodes of hemoptysis during menstruation, it sponta-
neously disappeared and then recurred two times in August
2005 (5mL/day) and January 2006 (5mL/day) during 57
months of follow-up. She also did not take any hormonal
agents during the follow-up. In patient no. 4, who presented
with the first episode of hemoptysis (10mL/day), hemopty-
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Figure 1 Chest CT scans at the diagnosis, subsequent inter-menses period and last follow-up in all four patients of catamenial
hemoptysis in which the ground-glass opacities were disappeared without any residual lesion.
J.-S. Ryu et al.1034sis spontaneously disappeared after six subsequent episodes
during menstruation. It did not recur during the 66 months
of follow-up. She got married in October 2004 and gave birth
in July 2005.Discussion
This study demonstrated that observation only could be an
alterative option in the treatment of catamenial hemopty-
sis. Hemoptysis is a very commonly encountered problem for
most clinicians. The decision on the treatment of hemop-
tysis by other etiologies has been made with the information
of the natural history of the causing diseases and its degree
of severity as measured by the amount.
In contrast with the observation only strategy presented
in this study, hormonal agents or surgical resection were
given to most reported patients of catameninal hemopty-
sis.3,4,6–17 Hormonal agents, including danazol, gonadotro-
pin-releasing hormone agonists, and oral contraceptives,
have been considered as the first option by clini-
cians.3,4,6,10–12,16–18 In patients showing adverse effects
from the hormonal agent or recurrence, surgical resection
has been used as the second option.3,4,7 In an early report
lobectomy was tried in the first treatment for hemoptysis.
The recent trend has been toward palliative treatment.
Parenchymal preserving surgical procedures such as video-
assisted thoracoscopic surgery were used to treat the
patients having single peripheral lesion.13,14 In addition,
palliative local treatment using Nd-YAG laser was reportedin the patients of centrally located, tracheobronchial
endometriosis.19,20
No data has been reported on the percentage of patients
who suffer from adverse reactions, or show recurrence after
hormonal agents or surgery. Unfortunately, current knowl-
edge on treatment of catamenial hemoptysis has arisen only
from the limited number of reported cases or experiences of
pelvic endometriosis, rather than from well designed,
controlled study. Because most patients from case series
already reported were almost in the age of hoping to be
pregnant, hormonal agents could be hard to be the
treatment option in the patients.
Determination of whether specific treatment is required
for all patients of catamenial hemoptysis remains unclear
for the following reasons. Firstly, there has been no report of
massive hemoptysis or mortality from catamenial hemopty-
sis. Secondly, it is unknown whether the implanted
endometrial cell behaves like normal tissue and operates
under hormonal influence or whether it is spontaneously
shed. Thirdly, the experiences from patients of pelvic
endometriosis showed that laparoscopic surgical resection
as a definitive treatment was also associated with sub-
stantial rates of recurrence, and that the use of hormonal
agents also carries adverse effects.5,21
In an average 58 months of follow-up, hemoptysis
spontaneously disappeared after subsequent continuations
of 2 or 6 months in three patients (patients nos. 2–4)
although one patient (no 3.) recurred two times synchro-
nously with her menstruation in the late of follow-up. Two of
three patients (patients nos. 2 and 4) became pregnant in
the late of follow-up. The fact that pregnancy is a kind of
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Therapeutic implications of patients with catamenial hemoptysis 1035hormonal treatment of catamenial hemoptysis could be
confounding factor in drawing a conclusion from this study.
Even if so, the hemoptysis was however ceased for 16 and
42 months without specific treatment before the preg-
nancy, respectively.
The chest CT scans in subsequent inter-menstrual
periods and at last follow-up were clear without any
residual change in all patients. These findings may suggest
the feasibility of spontaneous resolution of implanted
endometrial cells in lung parenchyma, in contrast to the
infrequent event in pelvic endometriosis mainly induced by
tubal regurgitation.
In the present study, all patients showed a relatively
small extent of GGO peripherally located on the chest CT
scan and underwent one or two episodes of dilatation and
curettage before onset of hemoptysis. Sampson’s theory of
transdiaphragmatic spread through tubal regurgitation
seems to be a lower possibility as pathogenic mechanism
of all four patients.22 Tubal regurgitation is a frequent
event observed in 76–90% of women.23,24 According to this
theory, the lower lobe of the lung would be expected to be
more likely affected and a larger amount of endometrial
cells would be expected to have migrated to the lung
rather than in lymphovascular embolization. However, the
present report of this was limited in making any definition
of the pathogenic mechanism. Therefore, a basic investi-
gation is needed to elucidate the mechanism and the
behavior of implanted endometrial cells.
Although diagnostic guideline of catamenial hemoptysis
is not available, present study has a limitation of not
performing flexible bronchoscopy that would be helpful in
identifying the source of bleeding, excluding other
tracheobronchial lesions, trying to obtain a pathological
confirmation or the possibility of centrally located airway
endometriosis.
This is first study of catamenial hemoptysis treatement
restricted to observation only with approximately five
years of follow-up duration and looking at the natural
history with a limitation of small number of cases. If a
patient has massive hemoptysis from catamenial hemop-
tysis, the benign results of this study, in which no patient
presented with massive hemoptysis, may not be applicable
and that intervention would be appropriate. We reported
that observation only could be an alternative to surgical
resection or long-term usage of hormonal agents, espe-
cially in the patients of hoping to be pregnant, or unwilling
to take surgical resection.References
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